Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Paxlovid and molnupiravir can reduce the risk of severe COVID-19, but they must be started within five days of symptom onset.
Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.
The new drugs must be used within a narrow window of time after developing symptoms.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.